Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
about
Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samplesMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsThe role of SPINK1 in ETS rearrangement-negative prostate cancersN-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancerCharacterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancerActive surveillance and focal therapy for low-intermediate risk prostate cancerDiagnosis of prostate cancer via nanotechnological approachDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsRecurrent rearrangements in prostate cancer: causes and therapeutic potentialDiscovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate TissueFusionSeq: a modular framework for finding gene fusions by analyzing Paired-End RNA-Sequencing dataFISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Role of the TMPRSS2-ERG gene fusion in prostate cancerGene Expression Differences in Prostate Cancers between Young and Old MenCelastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancerCNVs leading to fusion transcripts in individuals with autism spectrum disorderERG is a critical regulator of Wnt/LEF1 signaling in prostate cancerMolecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.Exosomes in prostate cancer: putting together the pieces of a puzzle.Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technologyTMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cellsAndrogen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response elementThe ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancerOptical coding of fusion genes using multicolor quantum dots for prostate cancer diagnosis.Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerNew strategies in prostate cancer: translating genomics into the clinicThe identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerInterrogating genomic and epigenomic data to understand prostate cancerMolecular genetics of prostate cancer: new prospects for old challengesFunctional antagonism of TMPRSS2-ERG splice variants in prostate cancer.Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation analysisThe pathogenesis of prostate cancer: from molecular to metabolic alterations.RNA-Seq mapping and detection of gene fusions with a suffix array algorithm.Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulationERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
P2860
Q21092937-F9FE447E-D71B-4810-B79C-8B3815BAADA1Q24629083-90EE7CD2-C362-41F3-90B1-3EA98395D4E4Q24647020-6078FE3D-2DB6-450F-A6DC-88FD603EA5FEQ24647034-D380A2EF-82E2-40BE-941D-C5FA3DCB421EQ24650647-CE01F41B-F4F3-43E0-9576-ECB8AD4B6EB5Q26773641-E4EC65D1-32AC-4864-AD64-F19F2C4BACA9Q26777322-7FCF93B7-27FC-4E3B-B5E8-54547AC3067BQ26829155-C7886A9F-B643-4AD8-8355-BD46C8AE487EQ26851525-B56C740C-09AD-4564-A0CE-978BA2679F47Q26997884-882FC337-261C-4CC2-BC2B-B7BAB8B739DDQ27499410-53249E44-0CAB-49B0-8DB0-5A76E3688E58Q27851411-9E84C762-8F55-4018-A3C1-1F9F2E14CE26Q28269156-6A473F88-1AF2-47A1-8E27-3712C94DA69DQ28468529-A43F4783-5C16-4270-89F5-60D9EE0AD40CQ28487695-A62962A7-C9A7-40E0-AEFF-48347CEBDF2AQ28716605-F7A832A6-C4DF-472A-8DF0-773D12FBF54CQ28771736-B0F4676B-0009-4A38-B71E-244251F813C5Q30479181-14D9D055-80CC-4D33-AA41-3F2548883478Q31042968-B9FDFEA0-F129-4530-A099-402BFE704A06Q33357387-65CBD112-8162-4056-ADAC-D736E93B716EQ33359279-EEE29312-F0A4-4C6D-B590-79B965B9AAB2Q33608762-6E69468A-C211-4679-8866-4E56773F2A63Q33648775-5059D2C7-2C3A-4A5D-8A60-0B75A655028FQ33663401-C06ABB5E-0868-4308-8ACD-5C0260F192E8Q33698635-D5433A2D-AA7A-4939-8D88-C6888DCB2DEBQ33812744-E36EE144-550E-4235-AFE7-538E1968EEA4Q33813603-33397436-E0E3-482F-B556-536EAA0F1F5AQ33862890-7A66954A-DBB9-4BE1-BFD5-5EDD6A2EA3D8Q34007943-C493E44D-3B93-4AFD-8C24-A32B9F26D17BQ34050388-F0119942-8AAB-4E4B-BC75-299A4397D984Q34125866-66D1517D-645D-4844-8321-72BED681ACEBQ34127462-F15A1C4A-5157-4C7E-A1B0-C2370B1D8006Q34170544-D8A447AA-DE5D-4DBD-BCEA-57E934CC1229Q34184661-7E6C66BF-6E62-4E66-9C05-BB34C69FE13CQ34201846-E93D2E7C-B865-4E6B-A81C-1AAA57E7212EQ34229580-D11B6CC0-1BDE-444A-B358-BB13714EADD1Q34296258-682604DA-7DEA-4F6D-A42A-941D4F5FE3CFQ34302881-3C224E26-FAE9-42C7-8A6B-C5CC2E299FBEQ34364174-7865C39F-DC96-4207-8C72-D2BC9952830FQ34411717-983A3405-5F99-476F-A904-B471D6A010DB
P2860
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Expression of variant TMPRSS2/ ...... th aggressive prostate cancer.
@en
type
label
Expression of variant TMPRSS2/ ...... th aggressive prostate cancer.
@en
prefLabel
Expression of variant TMPRSS2/ ...... th aggressive prostate cancer.
@en
P2093
P1433
P1476
Expression of variant TMPRSS2/ ...... th aggressive prostate cancer.
@en
P2093
Chengxi Ren
Jianghua Wang
Michael Ittmann
P304
P356
10.1158/0008-5472.CAN-06-1966
P407
P577
2006-09-01T00:00:00Z